Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe’s most valuable public company again. Now, the stock ...

The key ISM survey of activity in the U.S. services sector will be closely watched as investors continue to gauge the ...